Summary
GlobalData, the industry analysis specialist's new report, "Breast Cancer-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global breast cancer market,a key segment within the pharmaceutical and healthcare industry. The report identifies the key trends shaping and driving the global breast cancer market, within the oncology sector. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global breast cancer sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global breast cancer market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
-Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global breast cancer market.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with breast cancer. Key market players discussed include Bipar Sciences Inc, Biomira USA Inc, Apthera Inc, Novartis AG, OncoGenex Pharmaceuticals, Amgen, Johnson & Johnson, Schering-Plough and AstraZeneca.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global breast cancer market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global breast cancer market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Breast Cancer Market: Market Characterization 5
2.1 Overview 5
2.2 Breast Cancer Market Size 5
2.3 Breast Cancer Market Forecast and CAGR 5
2.4 Drivers and Barriers for the Breast Cancer Market 7
2.4.1 Drivers for the Breast Cancer Market 7
2.4.2 Barriers for the Breast Cancer Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Breast Cancer Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profiles of the Major Marketed Products in the Breast Cancer Market 11
3.3.1 Avastin (bevacizumab)+Paclitaxel 11
3.3.2 Arimidex (anastrozole) 12
3.3.3 Femara (letrozole) 13
3.3.4 Herceptin (trastuzumab) 15
3.3.5 Taxotere (docetaxel) 17
3.4 Key Takeaway 20
4 Breast Cancer Market: Pipeline Assessment 21
4.1 Overview 21
4.2 Strategic Pipeline Assessment 21
4.2.1 Technology Trends Analytic Framework 21
4.3 Breast Cancer Therapeutics-Promising Drugs under Clinical Development 23
4.4 Molecule Profile for Promising Drugs under Clinical Development 23
4.4.1 Afinitor 23
4.4.2 BSI-201 24
4.4.3 NeuVax 25
4.4.4 Stimuvax 25
4.4.5 Custirsen Sodium (OGX-011) 26
4.5 Breast Cancer Therapeutics Market-Clinical Pipeline by Mechanism of Action 26
4.6 Breast Cancer Pipeline-Pipeline by Clinical Phases of Development 27
4.6.1 Breast Cancer Therapeutics-Phase III Clinical Pipeline 28
4.6.2 Breast Cancer Therapeutics-Phase II Clinical Pipeline 41
4.6.3 Breast Cancer Therapeutics-Phase I Clinical Pipeline 80
4.6.4 Breast Cancer Therapeutics-Preclinical Pipeline 91
4.6.5 Discontinued/Suspended Drugs for Breast Cancer 94
4.7 Key Takeaway 94
5 Breast Cancer Market: Implications for Future Market Competition 96
6 Breast Cancer Market: Future Players in the Breast Cancer Market 97
6.1 Introduction 97
6.2 Novartis AG 97
6.2.1 Company Overview 97
6.2.2 Oncology Portfolio 98
6.2.3 Breast Cancer Portfolio 98
6.3 Oncogenex 99
6.3.1 Overview 99
6.3.2 Oncology Portfolio 99
6.3.3 Breast Cancer Product Portfolio 100
6.4 Apthera Inc 100
6.4.1 Overview 100
6.4.2 Oncology Portfolio 100
6.4.3 Breast Cancer Product Portfolio 101
6.5 BioNumerik Pharmaceuticals 101
6.5.1 Overview 101
6.5.2 Oncology Portfolio 102
6.6 Oncothyreon Inc 102
6.6.1 Overview 102
6.6.2 Oncology Portfolio 102
6.6.3 Breast Cancer Product Portfolio 103
6.7 Bipar Sciences 103
6.7.1 Overview 103
6.7.2 Oncology Portfolio 103
6.7.3 Breast Cancer Product Portfolio 104
7 Breast Cancer Market: Appendix 105
7.1 Market Definition 105
7.2 Abbreviations 105
7.3 Research Methodology 105
7.3.1 Coverage 106
7.3.2 Secondary Research 106
7.3.3 Forecasting 107
7.3.4 Primary Research 110
7.3.5 Expert Panels 110
7.4 Contact Us 110
7.5 Disclaimer 110
7.6 Sources 111

List of Tables
1.1 List of Tables
Table 1: Global Breast Cancer Market Forecast, 2001-2009 6
Table 2: Global Breast Cancer Market Forecast, 2009-2016 7
Table 3: Marketed Product Analysis in the Breast Cancer Market, 2010 19
Table 4: Breast Cancer Therapeutics-Most Promising Drugs under Clinical Development, 2010 23
Table 5: Breast Cancer Pipeline, Combinations, Phase III, 2010 28
Table 6: Breast Cancer Pipeline, Monotherapy, Phase III, 2010 38
Table 7: Breast Cancer Pipeline, Combinations, Phase II, 2010 41
Table 8: Breast Cancer Pipeline, Monotherapy, Phase II, 2010 69
Table 9: Breast Cancer Pipeline, Combinations, Phase I, 2010 80
Table 10: Breast Cancer Pipeline, Monotherapy, Phase I, 2010 86
Table 11: Breast Cancer Pipeline, Pre-clinical and Discovery Phase, 2010 91
Table 12: List of Discontinued Drugs for Breast Cancer, 2010 94
Table 13: Novartis-Oncology Pipeline, 2010 98
Table 14: OncoGeneX-Oncology Pipeline, 2010 99
Table 15: Apthera Inc-Oncology Pipeline, 2010 100
Table 16: BioNumerik Pharmaceuticals, Inc.-Oncology Pipeline, 2010 102
Table 17: Oncothyreon Inc-Oncology Pipeline, 2010 102
Table 18: BiPar Sciences-Oncology Pipeline, 2010 103

List of Figures
1.2 List of Figures
Figure 1: Global Breast Cancer Market Forecast, 2001-2009 6
Figure 2: Global Breast Cancer Market Forecast, 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Breast Cancer Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Marketed Products for Breast Cancer, 2010 10
Figure 5: Technology Trends Analytic Framework of the Breast Cancer Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of the Breast Cancer Pipeline-Description, 2010 22
Figure 7: Breast Cancer Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 27
Figure 8: Breast Cancer Pipeline by Phase of Clinical Development, 2010 27
Figure 9: Implications for Future Market Competition in the Breast Cancer Market, 2010 96
Figure 10: Breast Cancer Therapeutics Market-Clinical Pipeline by Company, 2010 97
Figure 11: GlobalData Methodology 106
Figure 12: GlobalData Market Forecasting Model 109